Trading Update
Full year revenues in line with consensus, adjusted operating profit marginally ahead with improved margins.
vs expectations: marginally ahead
- Full year Revenues in line with market consensus
- Adjusted operating profit marginally ahead of market consensus
- Net debt (pre IFRS 16) c.$185m
- Share buyback programme £40m (c.$54m)
- Alchemy Ingredients acquisition $22m
Select text to share a quote on X · sign in to keep highlights & notes in your ELM notes
Elementis plc ("Elementis" or the "Group"), a global specialty chemicals company, today issues its scheduled trading update for the three months and year ended 31 December 2025.
Elementis will publish its results for the financial year to 31 December 2025 on 5 March 2026.
Business performance
The Group has delivered a resilient performance with Revenues1 expected to be in line with market consensus2, despite the ongoing challenging market conditions.
Full year Group Adjusted operating profit1 is expected to be marginally ahead of market consensus2, with Adjusted operating margins1 ahead of last year. The improved margin performance has been driven by the benefits of our Elevate Elementis strategy and the positive changes being implemented across the Group, as we look to build on our strong foundations. These include: the simplification of our operational structure to enhance efficiency and agility, the bolt-on acquisition of UK based Alchemy Ingredients Limited ("Alchemy") in November 2025, as well as the ongoing delivery of our previously announced cost savings targets.
Balance sheet strength
The Group continues to generate positive free cash flow that gives us balance sheet strength and future capital allocation optionality.
Net debt pre IFRS 16 basis at the end of the financial year 2025 is expected to be c.$185m. This reflects several one-off cash payments during the year including: the successful completion of the Group's first share buyback programme for a total consideration of £40m (c.$54m), the previously announced disposal of the disused manufacturing site and associated environmental liabilities at Eaglescliffe, UK, for $11m, and the acquisition of Alchemy for $22m.
Chair succession
Further to the announcement on 29 October 2025, the Chair succession process continues to progress and an update will be provided in due course.
- Continuing operations basis.
- Based on company compiled consensus dated 20 January 2026, the mean revenue and adjusted operating profit for the year ended 31 December 2025 are $600m and $125m respectively.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.